MoonLake Locks In Sonelokimab Commercial Supply with Vetter Ahead of Q3 BLA
MLTX has more than doubled off its 52-week low of $5.95.
Summary
MoonLake Immunotherapeutics secured crucial commercial supply and capacity agreements with Vetter for the fill-finish manufacturing of its lead asset, sonelokimab. This follows the 8-K filed earlier today and builds on the positive pre-BLA meeting with the FDA and the Q3 2026 BLA submission target announced in May. These agreements are a significant step towards de-risking the supply chain and ensuring commercial readiness for sonelokimab's potential market launch. The company is targeting a Q3 2026 BLA submission for sonelokimab.
At the time of this announcement, MLTX was trading at $18.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.95 to $62.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.